MedPath

The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery

Not Applicable
Conditions
Sleep Deprivation
Delirium
Interventions
Drug: Placebo
Registration Number
NCT02691013
Lead Sponsor
University of California, San Diego
Brief Summary

Sleep deprivation is known to affect brain function but is often ignored in the sickest patients including those in the intensive care unit after major surgery. In these patients, the levels of melatonin can also be altered. Melatonin is a hormone secreted in the brain that maintains the body's sleep-wake, or circadian, cycle. The investigators want to test whether improving sleep quality affects the risk of developing confusion (delirium) in patients having clot removed from their lung (open heart surgery). In order to improve sleep quality, the investigators will conduct a study of Ramelteon, a medication that mimics the activity of melatonin and measure its effects on levels of melatonin and monitor sleep.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) who are admitted to UCSD for a planned PTE surgery.
  • Age > 18 years
Exclusion Criteria
  • Pregnancy
  • Cirrhosis of any etiology
  • Current use of any atypical antipsychotic including Fluvoxamine (contra-indicated with Ramelteon)
  • Any contraindication to EEG/Sleep recording
  • Non-English speaking (who are unable to complete delirium questionnaires)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPatients will receive a Placebo tablet every evening.
RamelteonRamelteonPatients will receive Ramelteon 8mg every evening.
Primary Outcome Measures
NameTimeMethod
Duration of DeliriumTwice daily for up to 10 days

Measured twice daily during the ICU stay using the Confusions Assessment Method instrument.

Total Duration of SleepDaily for up to 10 days

Participants wore an actigraphy device on their wrist for the duration of their ICU stay. This device continuously measures activity, and thus estimates sleep time.

Secondary Outcome Measures
NameTimeMethod
Number of Participants With DeliriumTwice daily for up to 10 days

Measured twice daily over the course of the ICU stay using the Confusion Assessment Method instrument

Measures of the Sound Levels in the Patient's Room3 days

Sound meter was placed at bedside in each patient room. This meter measured and recorded the sound level in decibels every two seconds.

Average Daily Critical Care Pain Observation Tool (CPOT)10 days

average daily pain level using the CPOT Participants can score from 0 to 6 on the CPOT scale, with 0 being no pain (calm, comfortable), and 6 representing significant pain/agitation.

Length of Hospital StayDuration of hospital admission
Length of ICU StayDuration of hospital admission
Measures of Light Quality in the Patient's Room3 days

Light meter placed at bedside in patient room; this meter measured and recorded the light level in lux for ever minutes.

© Copyright 2025. All Rights Reserved by MedPath